Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial [published correction appears in J Immunother Cancer. 2021 Aug;9(8):] - Ferris, R L; Spanos, W C; Leidner, R (J Immunother Cancer, 2021)